Oncology Early Phase / Multiple Disease Site Hematologic Malignancies Early Phase Team Lymphoma NHL Follicular Relapsed/Refractory 2 or more prior lines
Categories
Protocols
TENEOBIO-TENEOTWO-TNB486-001 Phase I OPEN TO ACCRUAL
A Multicenter, Phase 1, Open-Label, Dose-Escalation and Expansion Study of TNB-486, a Bispecific Antibody Targeting CD19 in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma